Figures & data
EoT: End of treatment; W: Week.
Future Oncology
Volume 18, 2022 - Issue 31
Clinical Trial Protocol
KEYNOTE – D36: Personalized Immunotherapy with a Neoepitope Vaccine, EVX-01 and Pembrolizumab in Advanced Melanoma
Georgina V Long1 Melanoma Institute Australia, The University of Sydney, & Royal North Shore & Mater Hospitals, Sydney, New South Wales, 2065, Australia
https://orcid.org/0000-0001-8894-3545
https://orcid.org/0000-0001-8894-3545, Pier Francesco Ferrucci2 Cancer Biotherapy Unit, Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, 20139, Italyhttps://orcid.org/0000-0001-6255-5851
https://orcid.org/0000-0001-6255-5851, Adnan Khattak3 Hollywood Private Hospital & Edith Cowan University, Perth, 6009, Australiahttps://orcid.org/0000-0002-4633-3818
https://orcid.org/0000-0002-4633-3818, , , , Thomas Trolle7 Evaxion Biotech A/S, Dr. Neergaards Vej 5F, Hørsholm, 2970, Denmarkhttps://orcid.org/0000-0003-0762-2198
https://orcid.org/0000-0003-0762-2198, & show all